{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T23:08:33Z","timestamp":1792192113883,"version":"4.4.0"},"reference-count":66,"publisher":"The Endocrine Society","issue":"12","license":[{"start":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T00:00:00Z","timestamp":1762819200000},"content-version":"vor","delay-in-days":7,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,11,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Context<\/jats:title>\n                    <jats:p>Individuals with psychiatric disorders have a higher prevalence of obesity, partly because of the use of psychotropic medications. Safe and effective pharmacological interventions for weight management in this population are needed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To assess the efficacy and safety of glucagon-like peptide-1 receptor agonists (GLP-1Ras) in individuals with psychiatric disorders and obesity\/overweight through a systematic review and meta-analysis, focusing on weight and metabolic outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data Sources<\/jats:title>\n                    <jats:p>We searched PubMed, Embase, Cochrane CENTRAL, and ClinicalTrials.gov until May 2025 for observational studies that evaluated GLP-1RAs in this population.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Study Selection<\/jats:title>\n                    <jats:p>Studies including adults with psychiatric disorders and obesity treated with GLP-1RAs were eligible; 10 randomized controlled trials met the inclusion criteria.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data Extraction<\/jats:title>\n                    <jats:p>Two reviewers independently extracted the data and assessed the risk of bias using the Cochrane RoB 2 tool. Outcomes included weight, body mass index (BMI), waist circumference, glucose level, systolic blood pressure, total cholesterol, high-density lipoprotein cholesterol, triglycerides, and adverse events.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data Synthesis<\/jats:title>\n                    <jats:p>GLP-1RAs significantly reduced body weight [mean difference (MD) \u22125.03\u2005kg; 95% confidence interval (CI): \u22126.04 to \u22124.01)], BMI (MD \u22121.59\u2005kg\/m\u00b2; 95% CI: \u22122 to \u22121.18), waist circumference (MD \u22123.4 cm 95% CI: \u22124.83 to\u22121.97), and fasting glucose (MD \u22120.29\u2005mmol\/L; 95% CI: \u22120.53 to \u22120.05) compared to controls. Gastrointestinal side effects were more frequent but generally mild and did not increase discontinuation rates.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>GLP-1RAs are effective and well-tolerated for managing obesity in psychiatric populations, offering significant weight and metabolic benefits. Further studies are needed to evaluate newer agents, such as semaglutide and tirzepatide, particularly in longer trials with standardized protocols.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1210\/jendso\/bvaf150","type":"journal-article","created":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T06:54:39Z","timestamp":1762844079000},"source":"Crossref","is-referenced-by-count":7,"title":["GLP-1R Agonists for Weight Loss in Psychiatric Disorders: A Systematic Review and Meta-analysis"],"prefix":"10.1210","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8462-7334","authenticated-orcid":false,"given":"Klara","family":"M\u00fcller Alves","sequence":"first","affiliation":[{"name":"Post-Graduate Program in Medical Sciences, Endocrinology, Federal University of Rio Grande do Sul , Porto Alegre 90035-903 ,","place":["Brazil"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0665-9271","authenticated-orcid":false,"given":"Manoela","family":"Teixeira da Silva","sequence":"additional","affiliation":[{"name":"Post-Graduate Program in Medical Sciences, Endocrinology, Federal University of Rio Grande do Sul , Porto Alegre 90035-903 ,","place":["Brazil"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1064-0100","authenticated-orcid":false,"given":"Caroline Kaercher","family":"Kramer","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, University of Toronto , Toronto, ON M5T 3L9 ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4392-4943","authenticated-orcid":false,"given":"Luciana Ver\u00e7oza","family":"Viana","sequence":"additional","affiliation":[{"name":"Post-Graduate Program in Medical Sciences, Endocrinology, Federal University of Rio Grande do Sul , Porto Alegre 90035-903 ,","place":["Brazil"]},{"name":"Division of Endocrinology, Hospital de Cl\u00ednicas de Porto Alegre , Porto Alegre 90035-903 ,","place":["Brazil"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2025,11,11]]},"reference":[{"issue":"4","key":"2025111101543435300_bvaf150-B1","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1001\/jamapsychiatry.2014.2502","article-title":"Mortality in mental disorders and global disease burden implications: a systematic review and meta-analysis","volume":"72","author":"Walker","year":"2015","journal-title":"JAMA Psychiatry"},{"issue":"10","key":"2025111101543435300_bvaf150-B2","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/S2215-0366(22)00237-1","article-title":"All-cause and cause-specific mortality among people with severe mental illness in Brazil's public health system, 2000\u201315: a retrospective study","volume":"9","author":"Melo","year":"2022","journal-title":"Lancet Psychiatry"},{"issue":"2","key":"2025111101543435300_bvaf150-B3","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1002\/j.2051-5545.2011.tb00036.x","article-title":"Physical illness in patients with severe mental disorders. Barriers to care, monitoring and treatment guidelines, plus recommendations at the system and individual level","volume":"10","author":"De Hert","year":"2011","journal-title":"World Psychiatry"},{"issue":"11","key":"2025111101543435300_bvaf150-B4","doi-asserted-by":"crossref","first-page":"752","DOI":"10.3109\/01612840.2012.708099","article-title":"Perceptions of barriers to physical health care for people with serious mental illness: a review of the international literature","volume":"33","author":"Happell","year":"2012","journal-title":"Issues Ment Health Nurs"},{"issue":"9","key":"2025111101543435300_bvaf150-B5","doi-asserted-by":"crossref","first-page":"589","DOI":"10.3109\/01612840.2011.569846","article-title":"The high prevalence of poor physical health and unhealthy lifestyle behaviours in individuals with severe mental illness","volume":"32","author":"Scott","year":"2011","journal-title":"Issues Ment Health Nurs"},{"issue":"3","key":"2025111101543435300_bvaf150-B6","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1002\/wps.20252","article-title":"Risk of metabolic syndrome and its components in people with schizophrenia and related psychotic disorders, bipolar disorder and major depressive disorder: a systematic review and meta-analysis","volume":"14","author":"Vancampfort","year":"2015","journal-title":"World Psychiatry"},{"issue":"6","key":"2025111101543435300_bvaf150-B7","doi-asserted-by":"crossref","first-page":"e36889","DOI":"10.1371\/journal.pone.0036889","article-title":"Changes in body weight and psychotropic drugs: a systematic synthesis of the literature","volume":"7","author":"Dent","year":"2012","journal-title":"PLoS One"},{"issue":"6","key":"2025111101543435300_bvaf150-B8","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.3945\/ajcn.2010.29203","article-title":"Longitudinal study of the diagnosis of components of the metabolic syndrome in individuals with binge-eating disorder","volume":"91","author":"Hudson","year":"2010","journal-title":"Am J Clin Nutr"},{"issue":"20","key":"2025111101543435300_bvaf150-B9","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.1001\/jama.2023.19897","article-title":"Obesity management in adults: a review","volume":"330","author":"Elmaleh-Sachs","year":"2023","journal-title":"JAMA"},{"issue":"6","key":"2025111101543435300_bvaf150-B10","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1159\/000502293","article-title":"Lifestyle interventions for weight management in people with serious mental illness: a systematic review with meta-analysis, trial sequential analysis, and meta-regression analysis exploring the mediators and moderators of treatment effects","volume":"88","author":"Speyer","year":"2019","journal-title":"Psychother Psychosom"},{"key":"2025111101543435300_bvaf150-B11","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.genhosppsych.2017.04.003","article-title":"Lifestyle interventions for weight loss among overweight and obese adults with serious mental illness: a systematic review and meta-analysis","volume":"47","author":"Naslund","year":"2017","journal-title":"Gen Hosp Psychiatry"},{"issue":"6","key":"2025111101543435300_bvaf150-B12","doi-asserted-by":"crossref","first-page":"e13435","DOI":"10.1111\/obr.13435","article-title":"Effect of glucagon-like peptide-1 receptor agonists on body weight in adults with obesity without diabetes mellitus: a systematic review and meta-analysis of randomized control trials","volume":"23","author":"Iqbal","year":"2022","journal-title":"Obes Rev"},{"issue":"2","key":"2025111101543435300_bvaf150-B13","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.eprac.2023.11.007","article-title":"Efficacy and safety of glucagon-like peptide-1 receptor agonists on body weight and cardiometabolic parameters in individuals with obesity and without diabetes: a systematic review and meta-analysis","volume":"30","author":"Ansari","year":"2024","journal-title":"Endocr Pract"},{"issue":"3","key":"2025111101543435300_bvaf150-B14","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/j.ajcnut.2023.04.017","article-title":"The weight-loss effect of GLP-1RAs in non-diabetic individuals with overweight or obesity: a systematic review with meta-analysis and trial sequential analysis of randomized controlled trials","volume":"118","author":"Liu","year":"2023","journal-title":"Am J Clin Nutr"},{"issue":"7","key":"2025111101543435300_bvaf150-B15","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1055\/a-1844-1176","article-title":"The antiobesity effect and safety of GLP-1 receptor agonist in overweight\/obese patients without diabetes: a systematic review and meta-analysis","volume":"54","author":"Guo","year":"2022","journal-title":"Horm Metab Res"},{"key":"2025111101543435300_bvaf150-B16","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.amjcard.2024.04.041","article-title":"Long-term efficacy and safety of once-weekly semaglutide for weight loss in patients without diabetes: a systematic review and meta-analysis of randomized controlled trials","volume":"222","author":"Moiz","year":"2024","journal-title":"Am J Cardiol"},{"issue":"3","key":"2025111101543435300_bvaf150-B17","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1056\/NEJMoa2206038","article-title":"SURMOUNT-1 Investigators. Tirzepatide once weekly for the treatment of obesity","volume":"387","author":"Jastreboff","year":"2022","journal-title":"N Engl J Med"},{"issue":"5","key":"2025111101543435300_bvaf150-B18","doi-asserted-by":"crossref","first-page":"e13717","DOI":"10.1111\/obr.13717","article-title":"Potent incretin-based therapy for obesity: a systematic review and meta-analysis","volume":"25","author":"M\u00fcllertz","year":"2024","journal-title":"Obes Rev"},{"key":"2025111101543435300_bvaf150-B19","doi-asserted-by":"crossref","first-page":"784","DOI":"10.3389\/fpsyt.2018.00784","article-title":"Feasibility, adherence and efficacy of liraglutide treatment in a sample of individuals with mood disorders and obesity","volume":"9","author":"Cuomo","year":"2019","journal-title":"Front Psychiatry"},{"issue":"4","key":"2025111101543435300_bvaf150-B20","doi-asserted-by":"crossref","first-page":"264","DOI":"10.7326\/0003-4819-151-4-200908180-00135","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"151","author":"Moher","year":"2009","journal-title":"Ann Intern Med"},{"key":"2025111101543435300_bvaf150-B21","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"Rob 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"2025111101543435300_bvaf150-B22","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions. Version 6.5.","author":"Higgins","year":"2024"},{"key":"2025111101543435300_bvaf150-B23","unstructured":"Alves KM, Silva MT, Kramer CK, Viana LV. GLP-1R agonists for weight loss in psychiatric disorders: a systematic review and meta-analysis\u2014Supplemental Material. \u00a0Figshare. Dataset. Deposited 5 September 2025. 10.6084\/m9.figshare.30067171.v1"},{"issue":"3","key":"2025111101543435300_bvaf150-B24","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.orcp.2015.03.005","article-title":"Improvement in binge eating in non-diabetic obese individuals after 3 months of treatment with liraglutide: a pilot study","volume":"9","author":"Robert","year":"2015","journal-title":"Obes Res Clin Pract"},{"issue":"2","key":"2025111101543435300_bvaf150-B25","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1111\/dom.12795","article-title":"Effect of GLP-1 receptor agonist on body weight in obese antipsychotic-treated patients with schizophrenia: a randomized, placebo-controlled trial","volume":"19","author":"Ish\u00f8y","year":"2017","journal-title":"Diabetes Obes Metab"},{"issue":"7","key":"2025111101543435300_bvaf150-B26","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1001\/jamapsychiatry.2017.1220","article-title":"Effect of liraglutide on prediabetes and overweight or obesity in clozapine- or olanzapine-treated patients with schizophrenia spectrum disorder: a randomized clinical trial","volume":"74","author":"Larsen","year":"2017","journal-title":"JAMA Psychiatry"},{"issue":"4","key":"2025111101543435300_bvaf150-B27","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1111\/dom.13167","article-title":"Treatment of clozapine-associated obesity and diabetes with exenatide in adults with schizophrenia: a randomized controlled trial (CODEX)","volume":"20","author":"Siskind","year":"2018","journal-title":"Diabetes Obes Metab"},{"issue":"4","key":"2025111101543435300_bvaf150-B28","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.dsx.2020.03.009","article-title":"Dulaglutide reduces binge episodes in type 2 diabetic patients with binge eating disorder: a pilot study","volume":"14","author":"Da Porto","year":"2020","journal-title":"Diabetes Metab Syndr"},{"issue":"6","key":"2025111101543435300_bvaf150-B29","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1111\/dom.14334","article-title":"The use of liraglutide in people with schizophrenia, schizoaffective disorder and first episode psychosis: results of a pilot randomized controlled trial","volume":"23","author":"Whicher","year":"2021","journal-title":"Diabetes Obes Metab"},{"issue":"2","key":"2025111101543435300_bvaf150-B30","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1002\/osp4.619","article-title":"A pilot randomized controlled trial of liraglutide 3.0\u2005mg for binge eating disorder","volume":"9","author":"Allison","year":"2022","journal-title":"Obes Sci Pract"},{"issue":"2","key":"2025111101543435300_bvaf150-B31","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1097\/JCP.0000000000001803","article-title":"Liraglutide in obese or overweight individuals with stable bipolar disorder","volume":"44","author":"McElroy","year":"2024","journal-title":"J Clin Psychopharmacol"},{"key":"2025111101543435300_bvaf150-B32","doi-asserted-by":"publisher","DOI":"10.2139\/ssrn.5164525","article-title":"Semaglutide for the treatment of cognitive dysfunction in major depressive disorder: a double-blind, placebo-controlled, randomised trial","author":"Badulescu","year":"2025","journal-title":"SSRN"},{"key":"2025111101543435300_bvaf150-B33","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.jad.2025.04.046","article-title":"A double-blind, placebo-controlled trial of exenatide for olanzapine-related weight gain in obese adults","volume":"382","author":"Patino","year":"2025","journal-title":"J Affect Disord"},{"issue":"5","key":"2025111101543435300_bvaf150-B34","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1017\/S1092852924000531","article-title":"A systematic review on the efficacy of GLP-1 receptor agonists in mitigating psychotropic drug-related weight gain","volume":"29","author":"Menon","year":"2024","journal-title":"CNS Spectr"},{"issue":"1","key":"2025111101543435300_bvaf150-B35","doi-asserted-by":"crossref","first-page":"355","DOI":"10.3892\/etm.2023.12054","article-title":"Therapeutic management of atypical antipsychotic related metabolic dysfunctions using GLP-1 receptor agonists: a systematic review","volume":"26","author":"Vasiliu","year":"2023","journal-title":"Exp Ther Med"},{"key":"2025111101543435300_bvaf150-B36","doi-asserted-by":"crossref","first-page":"1153648","DOI":"10.3389\/fpsyt.2023.1153648","article-title":"GLP-1 receptor agonists for cardiometabolic parameters in schizophrenia: a systematic review and meta-analysis","volume":"14","author":"Khaity","year":"2023","journal-title":"Front Psychiatry"},{"issue":"1","key":"2025111101543435300_bvaf150-B37","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1007\/s40519-025-01720-9","article-title":"GLP-1 agonists in the treatment of eating disorders: a systematic review and meta-analysis","volume":"30","author":"Radkhah","year":"2025","journal-title":"Eat Weight Disord"},{"issue":"3","key":"2025111101543435300_bvaf150-B38","doi-asserted-by":"crossref","first-page":"669","DOI":"10.3390\/biomedicines11030669","article-title":"Effect of glucagon-like peptide-1 receptor agonists on cardio-metabolic risk factors among obese\/overweight individuals treated with antipsychotic drug classes: an updated systematic review and meta-analysis of randomized controlled trials","volume":"11","author":"Patoulias","year":"2023","journal-title":"Biomedicines"},{"issue":"2","key":"2025111101543435300_bvaf150-B39","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1111\/dom.13522","article-title":"Glucagon-like peptide-1 receptor agonists for antipsychotic-associated cardio-metabolic risk factors: a systematic review and individual participant data meta-analysis","volume":"21","author":"Siskind","year":"2019","journal-title":"Diabetes Obes Metab"},{"issue":"10","key":"2025111101543435300_bvaf150-B40","doi-asserted-by":"crossref","first-page":"696","DOI":"10.5498\/wjp.v11.i10.696","article-title":"Metabolic disturbances associated with antipsychotic drug treatment in patients with schizophrenia: state-of-the-art and future perspectives","volume":"11","author":"Chang","year":"2021","journal-title":"World J Psychiatry"},{"key":"2025111101543435300_bvaf150-B41","doi-asserted-by":"crossref","first-page":"56672","DOI":"10.12775\/JEHS.2024.75.56672","article-title":"Glucagon-like peptide-1 receptor agonists as a therapeutic option for antipsychotic-induced obesity: a review of current evidence","volume":"75","author":"Gnia\u017a","year":"2024","journal-title":"J Educ Health Sport"},{"key":"2025111101543435300_bvaf150-B42","doi-asserted-by":"crossref","first-page":"e51","DOI":"10.1017\/neu.2025.6","article-title":"A systematic review on the role of glucagon-like peptide-1 receptor agonists on alcohol-related behaviors: potential therapeutic strategy for alcohol use disorder","volume":"37","author":"Zheng","year":"2025","journal-title":"Acta Neuropsychiatr"},{"issue":"4","key":"2025111101543435300_bvaf150-B43","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1001\/jamapsychiatry.2024.4789","article-title":"Once-weekly semaglutide in adults with alcohol use disorder: a randomized clinical trial","volume":"82","author":"Hendershot","year":"2025","journal-title":"JAMA Psychiatry"},{"issue":"3","key":"2025111101543435300_bvaf150-B44","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1177\/02537176241246744","article-title":"The potential role of GLP-1 agonists in psychiatric disorders: a paradigm shift in mental health treatment","volume":"46","author":"Gunturu","year":"2024","journal-title":"Indian J Psychol Med"},{"issue":"7","key":"2025111101543435300_bvaf150-B45","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1001\/jamapsychiatry.2025.0679","article-title":"Glucagon-like peptide 1 receptor agonists and mental health: a systematic review and meta-analysis","volume":"82","author":"Pierret","year":"2025","journal-title":"JAMA Psychiatry"},{"issue":"6","key":"2025111101543435300_bvaf150-B46","doi-asserted-by":"crossref","first-page":"e746","DOI":"10.4088\/JCP.15r10373","article-title":"Efficacy for psychopathology and body weight and safety of topiramate-antipsychotic cotreatment in patients with schizophrenia spectrum disorders: results from a meta-analysis of randomized controlled trials","volume":"77","author":"Correll","year":"2016","journal-title":"J Clin Psychiatry"},{"issue":"6","key":"2025111101543435300_bvaf150-B47","first-page":"19r02483","article-title":"Effectiveness of pharmacologic interventions in the management of weight gain in patients with severe mental illness: a systematic review and meta-analysis","volume":"21","author":"Hiluy","year":"2019","journal-title":"Prim Care Companion CNS Disord"},{"issue":"5","key":"2025111101543435300_bvaf150-B48","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1111\/acps.12631","article-title":"Efficacy and safety of adjunctive topiramate for schizophrenia: a meta-analysis of randomized controlled trials","volume":"134","author":"Zheng","year":"2016","journal-title":"Acta Psychiatr Scand"},{"issue":"3","key":"2025111101543435300_bvaf150-B49","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1111\/dom.16119","article-title":"Evaluation of the efficacy and safety of controlled-release phentermine\/topiramate in adults with obesity in Korea: a randomized, double-blind, placebo-controlled, phase 4 trial (QUEEN's study)","volume":"27","author":"Hong","year":"2025","journal-title":"Diabetes Obes Metab"},{"issue":"11","key":"2025111101543435300_bvaf150-B50","doi-asserted-by":"crossref","first-page":"2762","DOI":"10.1002\/oby.23898","article-title":"Naltrexone\/bupropion for binge-eating disorder: a randomized, double-blind, placebo-controlled trial","volume":"31","author":"Grilo","year":"2023","journal-title":"Obesity (Silver Spring)"},{"issue":"3","key":"2025111101543435300_bvaf150-B51","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1007\/s40519-020-00910-x","article-title":"An open-label trial on the efficacy and tolerability of naltrexone\/bupropion SR for treating altered eating behaviours and weight loss in binge eating disorder","volume":"26","author":"Carbone","year":"2021","journal-title":"Eat Weight Disord"},{"key":"2025111101543435300_bvaf150-B52","doi-asserted-by":"crossref","first-page":"100170","DOI":"10.1016\/j.obpill.2025.100170","article-title":"Appropriate use of the fixed-dose, extended-release combination of naltrexone and bupropion as treatment for obesity in primary care","volume":"14","author":"Lazarus","year":"2025","journal-title":"Obes Pillars"},{"issue":"9","key":"2025111101543435300_bvaf150-B53","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1001\/jamapsychiatry.2016.1232","article-title":"Metformin for treatment of overweight induced by atypical antipsychotic medication in young people with autism spectrum disorder: a randomized clinical trial [published correction appears in JAMA Psychiatry. 2016 Dec 1;73(12):1295. doi: 10.1001\/jamapsychiatry.2016.3189.]","volume":"73","author":"Anagnostou","year":"2016","journal-title":"JAMA Psychiatry"},{"issue":"31","key":"2025111101543435300_bvaf150-B54","doi-asserted-by":"crossref","first-page":"E875","DOI":"10.1503\/cmaj.191707","article-title":"Obesity in adults: a clinical practice guideline","volume":"192","author":"Wharton","year":"2020","journal-title":"CMAJ"},{"issue":"5","key":"2025111101543435300_bvaf150-B55","doi-asserted-by":"crossref","first-page":"114","DOI":"10.3892\/mmr.2025.13479","article-title":"Metabolic syndrome in patients with schizophrenia: underlying mechanisms and therapeutic approaches (Review)","volume":"31","author":"Manta","year":"2025","journal-title":"Mol Med Rep"},{"issue":"2","key":"2025111101543435300_bvaf150-B56","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1007\/s00125-010-1937-z","article-title":"Metformin regulates the incretin receptor axis via a pathway dependent on peroxisome proliferator-activated receptor-\u03b1 in mice","volume":"54","author":"Maida","year":"2011","journal-title":"Diabetologia"},{"issue":"10","key":"2025111101543435300_bvaf150-B57","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/S2213-8587(19)30249-9","article-title":"Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials","volume":"7","author":"Kristensen","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"2","key":"2025111101543435300_bvaf150-B58","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S2213-8587(17)30412-6","article-title":"Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis","volume":"6","author":"Bethel","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2025111101543435300_bvaf150-B59","doi-asserted-by":"crossref","first-page":"103020","DOI":"10.1016\/j.eclinm.2024.103020","article-title":"Safety and effects of anti-obesity medications on weight loss, cardiometabolic, and psychological outcomes in people living with overweight or obesity: a systematic review and meta-analysis","volume":"79","author":"Liu","year":"2024","journal-title":"EClinicalMedicine"},{"issue":"5","key":"2025111101543435300_bvaf150-B60","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1093\/schbul\/sbae205","article-title":"Metformin for the prevention of antipsychotic-induced weight gain: development of guidelines and validation of consensus","volume":"51","author":"Carolan","year":"2024","journal-title":"Schizophr Bull"},{"issue":"11","key":"2025111101543435300_bvaf150-B61","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-weekly semaglutide in adults with overweight or obesity","volume":"384","author":"Wilding","year":"2021","journal-title":"N Engl J Med"},{"issue":"2","key":"2025111101543435300_bvaf150-B62","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1001\/jama.2021.23619","article-title":"Effect of weekly subcutaneous semaglutide vs daily liraglutide on body weight in adults with overweight or obesity without diabetes: the STEP 8 randomized clinical trial","volume":"327","author":"Rubino","year":"2022","journal-title":"JAMA"},{"issue":"5","key":"2025111101543435300_bvaf150-B63","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1177\/87551225221110850","article-title":"Effect of antidepressants on glucagon-like peptide-1 receptor agonist-related weight loss","volume":"38","author":"Durell","year":"2022","journal-title":"J Pharm Technol"},{"key":"2025111101543435300_bvaf150-B64","doi-asserted-by":"crossref","first-page":"e076410","DOI":"10.1136\/bmj-2023-076410","article-title":"Comparative effectiveness of GLP-1 receptor agonists on glycaemic control, body weight, and lipid profile for type 2 diabetes: systematic review and network meta-analysis","volume":"384","author":"Yao","year":"2024","journal-title":"BMJ"},{"issue":"1","key":"2025111101543435300_bvaf150-B65","doi-asserted-by":"crossref","first-page":"e068652","DOI":"10.1136\/bmjopen-2022-068652","article-title":"Effect of the GLP-1 receptor agonist semaglutide on metabolic disturbances in clozapine-treated or olanzapine-treated patients with a schizophrenia spectrum disorder: study protocol of a placebo-controlled, randomised clinical trial (SemaPsychiatry)","volume":"13","author":"Sass","year":"2023","journal-title":"BMJ Open"},{"issue":"3","key":"2025111101543435300_bvaf150-B66","doi-asserted-by":"crossref","first-page":"e077173","DOI":"10.1136\/bmjopen-2023-077173","article-title":"Home-based intervention with semaglutide treatment of neuroleptic-related prediabetes (HISTORI): protocol describing a prospective, randomised, placebo-controlled and double-blinded multicentre trial","volume":"14","author":"Ganeshalingam","year":"2024","journal-title":"BMJ Open"}],"container-title":["Journal of the Endocrine Society"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jes\/article-pdf\/9\/12\/bvaf150\/65267345\/bvaf150.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jes\/article-pdf\/9\/12\/bvaf150\/65267345\/bvaf150.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T06:54:49Z","timestamp":1762844089000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jes\/article\/doi\/10.1210\/jendso\/bvaf150\/8320247"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,4]]},"references-count":66,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,11,4]]}},"URL":"https:\/\/doi.org\/10.1210\/jendso\/bvaf150","relation":{},"ISSN":["2472-1972"],"issn-type":[{"value":"2472-1972","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,12]]},"published":{"date-parts":[[2025,11,4]]},"article-number":"bvaf150"}}